Literature DB >> 32720224

Genomic profile and immune contexture in colorectal cancer-relevance for prognosis and immunotherapy.

Sandra Meršaková1, Zora Lasabová2, Ján Strnádel3, Michal Kalman4, Eva Gabonova5, Peter Sabaka6, Rachele Ciccocioppo7, Luis Rodrigo8, Peter Kruzliak9, Peter Mikolajčík5.   

Abstract

Colorectal cancer (CRC) is one of the leading cancers in both genders. TNM staging system is still the most commonly used tumor classification and prognostic system. The disadvantage of TNM is that the prognostic information it provides is incomplete, and patients with the same histological tumor stages may differ significantly in the clinical outcome. Therefore, the identification of new prognostic parameters is crucial. The carcinogenic process that gives rise to an individual tumor is unique and tumor microenviroment should be taken into consideration. In CRC, T-cell infiltration is not homogenous, and recent studies are mostly focusing on memory T-cells and CD8 cells in predicting disease-free survival (DFS) and overall survival (OS). It seems that DFS and OS are not only dependent on microsatellite instable or stable status but mostly on the levels of expression of the immune signatures. Also, patients with high infiltration of cytotoxic and memory cells have significantly better outcome. This review consolidates current knowledge and recent research about importance of immune-cell-associated proteins, specific gene profiles of immune cells and immunotherapy in CRC. We also discussed cell-specific signatures in cancer treatment.

Entities:  

Keywords:  Colorectal cancer (CRC); Genomic profile; Immune cells; Immunotherapy

Year:  2020        PMID: 32720224     DOI: 10.1007/s10238-020-00649-w

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  53 in total

Review 1.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

2.  Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.

Authors:  Pauline Maby; David Tougeron; Mohamad Hamieh; Bernhard Mlecnik; Hafid Kora; Gabriela Bindea; Helen K Angell; Tessa Fredriksen; Nicolas Elie; Emilie Fauquembergue; Aurélie Drouet; Jérôme Leprince; Jacques Benichou; Jacques Mauillon; Florence Le Pessot; Richard Sesboüé; Jean-Jacques Tuech; Jean-Christophe Sabourin; Pierre Michel; Thierry Frébourg; Jérôme Galon; Jean-Baptiste Latouche
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

3.  Mutation analysis of POLE gene in patients with early-onset colorectal cancer revealed a rare silent variant within the endonuclease domain with potential effect on splicing.

Authors:  Zora Lasabová; Michal Kalman; Veronika Holubeková; Marián Grendár; Ivana Kašubová; Karin Jašek; Sandra Meršaková; Bibiana Malicherová; Denis Baranenko; Mariusz Adamek; Peter Kruzliak; Lukáš Plank
Journal:  Clin Exp Med       Date:  2019-05-02       Impact factor: 3.984

4.  Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations.

Authors:  David Tougeron; Emilie Fauquembergue; Alexandre Rouquette; Florence Le Pessot; Richard Sesboüé; Michèle Laurent; Pascaline Berthet; Jacques Mauillon; Frédéric Di Fiore; Jean-Christophe Sabourin; Pierre Michel; Mario Tosi; Thierry Frébourg; Jean-Baptiste Latouche
Journal:  Mod Pathol       Date:  2009-06-05       Impact factor: 7.842

Review 5.  Resolving genetic heterogeneity in cancer.

Authors:  Samra Turajlic; Andrea Sottoriva; Trevor Graham; Charles Swanton
Journal:  Nat Rev Genet       Date:  2019-07       Impact factor: 53.242

Review 6.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

7.  A Big Bang model of human colorectal tumor growth.

Authors:  Andrea Sottoriva; Haeyoun Kang; Zhicheng Ma; Trevor A Graham; Matthew P Salomon; Junsong Zhao; Paul Marjoram; Kimberly Siegmund; Michael F Press; Darryl Shibata; Christina Curtis
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

Review 8.  Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence.

Authors:  Teresa Troiani; Stefania Napolitano; Carminia Maria Della Corte; Giulia Martini; Erika Martinelli; Floriana Morgillo; Fortunato Ciardiello
Journal:  ESMO Open       Date:  2016-09-16

9.  Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.

Authors:  Chanthirika Ragulan; Katherine Eason; Elisa Fontana; Gift Nyamundanda; Noelia Tarazona; Yatish Patil; Pawan Poudel; Rita T Lawlor; Maguy Del Rio; Si-Lin Koo; Wah-Siew Tan; Francesco Sclafani; Ruwaida Begum; Larissa S Teixeira Mendes; Pierre Martineau; Aldo Scarpa; Andrés Cervantes; Iain Beehuat Tan; David Cunningham; Anguraj Sadanandam
Journal:  Sci Rep       Date:  2019-05-21       Impact factor: 4.379

10.  The consensus molecular subtypes of colorectal cancer.

Authors:  Justin Guinney; Rodrigo Dienstmann; Xin Wang; Aurélien de Reyniès; Andreas Schlicker; Charlotte Soneson; Laetitia Marisa; Paul Roepman; Gift Nyamundanda; Paolo Angelino; Brian M Bot; Jeffrey S Morris; Iris M Simon; Sarah Gerster; Evelyn Fessler; Felipe De Sousa E Melo; Edoardo Missiaglia; Hena Ramay; David Barras; Krisztian Homicsko; Dipen Maru; Ganiraju C Manyam; Bradley Broom; Valerie Boige; Beatriz Perez-Villamil; Ted Laderas; Ramon Salazar; Joe W Gray; Douglas Hanahan; Josep Tabernero; Rene Bernards; Stephen H Friend; Pierre Laurent-Puig; Jan Paul Medema; Anguraj Sadanandam; Lodewyk Wessels; Mauro Delorenzi; Scott Kopetz; Louis Vermeulen; Sabine Tejpar
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

View more
  1 in total

1.  Ferroptosis-related genes are potential prognostic molecular markers for patients with colorectal cancer.

Authors:  Yanliang Liu; Fengqin Guo; Wenyi Guo; Yatao Wang; Wei Song; Tao Fu
Journal:  Clin Exp Med       Date:  2021-03-06       Impact factor: 3.984

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.